|
FIG 1. Case 12: 58-year-old man with GBM treated with carboplatin and thalidomide, without concomitant steroid therapy.
A–C, Postcontrast T1-weighted images. At the start of therapy, an irregularly enhancing mass is seen in the left parietooccipital region (A). At 4-month follow-up, there is mild interval increase in contrast enhancement (B). At 8-month follow-up, a new area of abnormal contrast enhancement is seen in the splenium of the corpus callosum (arrow) as well as lateral periatrial and ventricular involvement (C).
D–F, Corresponding color overlay images. At the start of therapy, a focal area of hyperperfusion (arrow) is seen in the lateral aspect of the left parietooccipital tumor (D). At 4-month follow-up, there is interval decrease in the perfusion abnormality in the same region (arrow) (E). At 8-month follow-up, almost complete resolution of the perfusion abnormality is noted in the left parietooccipital lobe (arrow). There is no abnormal perfusion corresponding to the contrast enhancement within the splenium of the corpus callosum. Although conventional imaging findings are consistent with tumor progression, a lack of perfusion abnormality suggests otherwise. The patient was clinically stable at 12- and 16-month follow-up examinations (F).
|